Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

One Year Follow-Up of Children and Adolescents With Chronic Immune Thrombocytopenic Purpura (ITP) Treated With Rituximab PEDIATRIC BLOOD & CANCER Mueller, B. U., Bennett, C. M., Feldman, H. A., Bussel, J. B., Abshire, T. C., Moore, T. B., Sawaf, H., Loh, M. L., Rogers, Z. R., Glader, B. E., McCarthy, M. C., Mahoney, D. H., Olson, T. A., Feig, S. A., Lorenzana, A. N., Mentzer, W. C., Buchanan, G. R., Neufeld, E. J. 2009; 52 (2): 259-262

Abstract

We previously showed in a prospective study that rituximab appears to be effective in some children and adolescents with severe chronic immune thrombocytopenia. Eleven of 36 patients achieved and maintained platelet counts over 50,000/mm(3) within the first 12 weeks. These patients were followed for the next year.Platelet counts were monitored monthly and all subsequent bleeding manifestations and need for further treatment was noted.Eight of the 11 initial responders maintained a platelet count over 150,000/mm(3) without further treatment intervention. Three patients had a late relapse. One initial non-responder achieved a remission after 16 weeks, and two additional patients maintained platelet counts around 50,000/mm(3) without the need for further intervention.Rituximab resulted in sustained efficacy with platelet counts of 50,000/mm(3) or higher in 11 of 36 patients (31%).

View details for DOI 10.1002/pbc.21757

View details for Web of Science ID 000261796000025

View details for PubMedID 18937333